NTRA-2112 not checked

Elgan Pharma Ltd.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Premature Birth of Newborn, Intestinal Malabsorption
Main trialPhase 3
“The study will evaluate the effect of NTRA-2112 on intestinal malabsorption in preterm infants.”In the company’s words, NCT02510560 on ClinicalTrials.gov

Other drugs for Premature Birth of Newborn

All 3 drugs for Premature Birth of Newborn

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Terminated 25 Apr 2018 Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow NTRA-2112

Following is part of Solo: you see every change to NTRA-2112 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in